175 related articles for article (PubMed ID: 24473786)
1. Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders.
Corradini P; Carniti C
Methods Mol Biol; 2014; 1109():209-37. PubMed ID: 24473786
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease detection in lymphoma and multiple myeloma: impact on therapeutic paradigms.
Ferrero S; Drandi D; Mantoan B; Ghione P; Omedè P; Ladetto M
Hematol Oncol; 2011 Dec; 29(4):167-76. PubMed ID: 22678691
[TBL] [Abstract][Full Text] [Related]
3. Significance of minimal residual disease in lymphoid malignancies.
Brüggemann M; Pott C; Ritgen M; Kneba M
Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for stem cell transplantation in indolent lymphomas.
Gribben JG
Cancer J Sci Am; 1998 Jul; 4 Suppl 2():S37-45. PubMed ID: 9672773
[TBL] [Abstract][Full Text] [Related]
5. Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.
Fenk R; Ak M; Kobbe G; Steidl U; Arnold C; Korthals M; Hünerlitürkoglu A; Rohr UP; Kliszewski S; Bernhardt A; Haas R; Kronenwett R
Haematologica; 2004 May; 89(5):557-66. PubMed ID: 15136219
[TBL] [Abstract][Full Text] [Related]
6. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies.
Moos M; Schulz R; Cremer F; Sucker C; Schmohl D; Döhner H; Goldschmidt H; Haas R; Hunstein W
Stem Cells; 1995 Dec; 13 Suppl 3():42-51. PubMed ID: 8747988
[TBL] [Abstract][Full Text] [Related]
7. Depth of response assessed by quantitative ASO-PCR predicts the outcome after stem cell transplantation in multiple myeloma.
Putkonen M; Kairisto V; Juvonen V; Pelliniemi TT; Rauhala A; Itälä-Remes M; Remes K
Eur J Haematol; 2010 Nov; 85(5):416-23. PubMed ID: 20722702
[TBL] [Abstract][Full Text] [Related]
8. Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.
Elmaagacli AH
Methods Mol Biol; 2014; 1109():187-207. PubMed ID: 24473785
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease markers before and after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Dominietto A
Curr Opin Hematol; 2011 Nov; 18(6):381-7. PubMed ID: 21986564
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease as a surrogate marker for risk assignment to ALL patients.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Rev Clin Exp Hematol; 2003 Sep; 7(3):292-323. PubMed ID: 15024971
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
12. Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.
Brüggemann M; Gökbuget N; Kneba M
Semin Oncol; 2012 Feb; 39(1):47-57. PubMed ID: 22289491
[TBL] [Abstract][Full Text] [Related]
13. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
14. [The minimal residual disease (MRD) in hematological malignancies].
Yokota S; Okamoto T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):762-8. PubMed ID: 11432342
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.
Cazzaniga G; Biondi A
Haematologica; 2005 Mar; 90(3):382-90. PubMed ID: 15749670
[TBL] [Abstract][Full Text] [Related]
16. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
17. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.
Candoni A; Toffoletti E; Gallina R; Simeone E; Chiozzotto M; Volpetti S; Fanin R
Clin Transplant; 2011; 25(2):308-16. PubMed ID: 20412098
[TBL] [Abstract][Full Text] [Related]
19. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.
Galimberti S; Benedetti E; Morabito F; Papineschi F; Callea V; Fazzi R; Stelitano C; Andreazzoli F; Guerrini F; Ciabatti E; Martino M; Nobile F; Iacopino P; Petrini M
Leuk Res; 2005 Aug; 29(8):961-6. PubMed ID: 15978948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
